Female doctor with a stethoscope advising a clinical trial participant.

Immunic Therapeutics

Developing Selective
Oral Drugs in Immunology

Immunic is a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases.

About Us

Advanced Development Pipeline

Differentiated Programs in Clinical Development

We are developing orally administered, small molecule programs, each of which has unique features intended to directly address the unmet needs of patients with serious chronic inflammatory and autoimmune diseases.

About Our Pipeline

Targeting Multiple Sclerosis

Elevate the Standard of Care With a Holistic Solution for Multiple Sclerosis Patients

Our mission is to develop high-quality, oral treatment options with comprehensive therapeutic efficacy and outstanding safety and tolerability for patients with multiple sclerosis.

About Vidofludimus Calcium

Targeting Celiac Disease

Making New, Convenient, Oral Treatment Options Available to Celiac Disease Patients

We aim to offer new, efficacious, safe and well-tolerated orally available treatment options to patients suffering from celiac disease in order to improve their lives by eliminating the debilitating symptoms of the disease.

About IMU-856

Latest News

View All

October 7, 2026

Immunic to Present New Clinical, Biomarker and Preclinical Data on Vidofludimus Calcium at MSToronto2026 – the 10th Joint ACTRIMS-ECTRIMS Meeting

September 29, 2026

Immunic Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 2, 2026

Immunic to Host Virtual Relapsing Multiple Sclerosis R&D Day on September 9, 2026

"I think of Immunic as a mission before it's a company — to change the lives of people with multiple sclerosis today, and to keep pushing the innovations that will reshape neurodegenerative diseases tomorrow. I get to do the two things I love most in service of it: turn bold science into real treatments, and build a team that accomplishes the seemingly impossible together."

Erik Lundgren

Chief Executive Officer

“I have been so fortunate to spend my professional career in the pharmaceutical industry, where I have had the opportunity to positively impact the lives of countless human beings living with serious diseases. There is nothing more rewarding than developing a new medicine and can bring hope where there was no hope. This is our ultimate goal here at Immunic, to address unmet needs for individuals living with chronic inflammatory and autoimmune diseases.”

Jason Tardio

President and Chief Operating Officer

“It is my passion to be a member of an emerging company working with a team of extremely talented people, all focused in the same direction, with the goal of bringing life changing therapies to patients.”

Glenn Whaley

Chief Financial Officer

“Beautiful science should be translated into a better life for patients, otherwise, it’s still beautiful, but useless.”

Dr. Hella Kohlhof

Chief Scientific Officer

“Finding treatments for neurological disorders has been a personal and unwavering mission throughout my career. My motto: “Aut viam inveniam aut faciam” or “I’ll either find a way or make one.” This is my commitment to the patients we serve.”

Dr. Michael A. Panzara

Chief Medical Officer

“I have a personal, long-lasting commitment to make every day count for those who need it most. I am, therefore, grateful that at Immunic we have an innate sense of urgency to make a difference, turning scientific breakthroughs into therapies that offer hope, improved health outcomes and meaningful improvements that change patients’ lives.”

Werner Gladdines

Chief Development Officer

"Technology can be a powerful force multiplier for pharmaceutical companies, and its impact begins with a strong data and digital foundation. Building these capabilities has been a deeply meaningful part of my life’s mission. What inspires me most about Immunic is the opportunity to empower our people to move promising science forward and, ultimately, bring greater hope and better outcomes to patients and their families."

Chitrang Davé

Chief Data and Digital Officer

“My focus is, not only, to review and approve documents but to collaborate with my amazing colleagues in order to make a substantial impact for patients while creating long-term value for our investors and other stakeholders.”

Inderpal Singh

General Counsel

“Having a positive impact on patients’ lives is the ultimate objective. As a team, we must seize the opportunities to maximize the potential of our programs so that we may also maximize the benefits for patients.“

Patrick Walsh

Chief Business Officer